Pharmaceuticals, Biotechnology and Life Sciences
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
Arcturus Therapeutics and Catalent have entered a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.
NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into…
On Thursday, March 16, 2017, the Dow Jones Industrial Average and the S&P 500 edged 0.07% and 0.16% lower, respectively, at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.01%. Five out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, Stock-Callers.com assessed the several drugs – generic equities on Friday.